表紙
市場調査レポート

PharmaPoint:季節性インフルエンザワクチン - 世界の医薬品の予測と市場分析

PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update

発行 GlobalData 商品コード 296463
出版日 ページ情報 英文 332 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
PharmaPoint:季節性インフルエンザワクチン - 世界の医薬品の予測と市場分析 PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update
出版日: 2013年09月30日 ページ情報: 英文 332 Pages
概要

季節性インフルエンザは、インフルエンザウイルスにより引き起こされる呼吸器感染症で、高熱・悪寒・咳といった中〜重度の症状を伴います。市場は予防接種用ワクチンの売上高に大きく依存しています。現在は三価ワクチンの筋肉内接種が大半を占めていますが、新たな投与方法つきのワクチンが提供されるようになると、従来型の接種方法からの移行が進むものと思われます。更に、今後は四価ワクチンの発売とシェア拡大も生じると考えられます。

当レポートでは、全世界の季節性インフルエンザワクチン市場の現状と将来展望について分析し、疾患の概要や今後の疫学的予測、主要国での予防体性、主要企業のプロファイルと代表的製品、市場のアンメットニーズと将来的な機会、現在治験中のパイプライン製品の情報、今後の市場規模と影響要因などを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態
    • 病因
    • 病態生理
  • 症状
  • 予後

第4章 疫学

  • リスク要因と共存症
  • 世界各地での傾向
    • 米国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • 英国
    • 日本
    • 中国
    • インド
  • 予測手法
    • 利用した情報源
    • 予測の前提条件と手法
  • 疫学的予測(今後11年間分)
    • 季節性インフルエンザのワクチン接種率
  • 議論
    • 世界各国のワクチン摂取率の見通し
    • 分析の限界
    • 分析の強み

第5章 疾患の管理

  • インフルエンザ予防接種政策
  • 米国
    • インフルエンザ予防接種の推奨・政策
    • 臨床診療
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • 中国
  • インド

第6章 競争環境

  • 概要
  • 競合企業の戦略的評価
  • 製品プロファイル:主要ブランド
    • Fluzone
    • Vaxigrip/Mutagrip
    • Fluarix/FluLaval
    • FluMist
    • Fluzone High-Dose
    • Fluad
    • Fluzone ID (Intradermal)/Intanza
    • Optaflu/Flucelvax
    • Flublok
    • Fluvirin
    • Afluria
    • Influvac
    • Agrippal

第7章 市場機会とアンメットニーズ

  • 概要
  • アンメットニーズ
    • 高い患者認識の水準
    • 高齢者・子供(2歳以下)における効能の向上
    • 改善したワクチン副作用のプロファイル
    • より効率的なワクチン製造プロセス
    • よりコスト効果的なワクチン
  • ギャップ分析
  • 市場機会
    • ウィルス株に対する防御幅の拡大
    • 防御持続期間の増加
    • T細胞の関与

第8章 パイプライン評価

  • 概要
  • 治験マッピング(国別)
  • 相別・治験段階別の治験進行状況
  • パイプラインの戦略的評価
    • ASP7374 (UMN-0502)
    • インフルエンザウイルス様粒子(VLP)ワクチン

第9章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の概要
  • 企業プロファイル
    • Sanofi
    • AstraZeneca (MedImmune)
    • Novartis
    • GlaxoSmithKline
    • CSL Biotherapies
    • Abbott
    • Protein Sciences Corporation
    • Novavax

第10章 市場の見通し

  • 世界市場
    • 市場予測
    • 市場促進・阻害要因:世界的課題
  • 米国
    • 市場予測
    • 近年の主な出来事
    • 市場促進・阻害要因
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • 中国
  • インド

第11章 付録

図表一覧

目次
Product Code: GDHC67PIDR

Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

Highlights

Key Questions Answered

  • How big an impact will quadrivalent vaccines have on the seasonal influenza market? What do key opinion leaders think of this paradigm shift?
  • What are the key vaccines for each segment in the population?
  • Will vaccines with novel routes of administration face adoption challenges in the market? What is the projected uptake of intranasal FluMist or intradermal vaccines, like Fluzone IntraDermal, over the forecast period?
  • The developmental pipeline consists of cell culture based vaccines. Which of these vaccines will attain high sales revenues during 2012-2022 and in which markets?
  • What governmental and industry changes are likely to change the vaccination rates in the markets researched? Which is the biggest growth market globally?

Key Findings

  • Quadrivalent vaccines are expected to cannibalize sales of trivalent vaccines or overtake trivalent vaccine sales.
  • New market entrants will increase competitiveness in the areas of production, manufacturing, fidelity to circulating influenza strains and strength of immune response elicited.
  • The initiation of a government initiative in the UK with Fluenz (FluMist) is anticipated to dramatically change market dynamics.

Scope

  • Overview of seasonal influenza, including epidemiology, etiology, general symptoms from infection, and national vaccination recommendations and guidelines.
  • Annualized seasonal influenza vaccine market revenue, annual cost of vaccination and treatment usage pattern data from 2012 and forecast for ten years to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the seasonal influenza market.
  • Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically cell culture based vaccines and quadrivalent vaccines with novel routes of administration.
  • Analysis of the current and future market competition in the global seasonal influenza vaccine market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global seasonal influenza vaccine market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global seasonal influenza vaccine market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global seasonal influenza vaccine market from 2012-2022.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis

4. Epidemiology

  • 4.1. Risk Factors and Comorbidities
  • 4.2. Global Trends
    • 4.2.1. United States
    • 4.2.2. France
    • 4.2.3. Germany
    • 4.2.4. Italy
    • 4.2.5. Spain
    • 4.2.6. United Kingdom
    • 4.2.7. Japan
    • 4.2.8. China
    • 4.2.9. India
  • 4.3. Forecast Methodology
    • 4.3.1. Sources Used
    • 4.3.2. Forecast Assumptions and Methods
  • 4.4. Epidemiological Forecast (2012-2022)
    • 4.4.1. Seasonal Influenza Vaccination Coverage, N (%)
  • 4.5. Discussion
    • 4.5.1. Global Vaccination Coverage Outlook
    • 4.5.2. Limitations in Analysis
    • 4.5.3. Strengths of Analysis

5. Disease Management

  • 5.1. Influenza Vaccination Policy
  • 5.2. United States
    • 5.2.1. Influenza Vaccination Recommendations and Policies
    • 5.2.2. Clinical Practice
  • 5.3. France
    • 5.3.1. Influenza Vaccination Recommendations and Policies
    • 5.3.2. Clinical Practice
  • 5.4. Germany
    • 5.4.1. Influenza Vaccination Recommendations and Policies
    • 5.4.2. Clinical Practice
  • 5.5. Italy
    • 5.5.1. Influenza Vaccination Recommendations and Policies
    • 5.5.2. Clinical Practice
  • 5.6. Spain
    • 5.6.1. Influenza Vaccination Recommendations and Policies
    • 5.6.2. Clinical Practice
  • 5.7. United Kingdom
    • 5.7.1. Influenza Vaccination Recommendations and Policies
    • 5.7.2. Clinical Practice
  • 5.8. Japan
    • 5.8.1. Influenza Vaccination Recommendations and Policies
    • 5.8.2. Clinical Practice
  • 5.9. China
    • 5.9.1. Influenza Vaccination Recommendations and Policies
    • 5.9.2. Clinical Practice
  • 5.10. India
    • 5.10.1. Influenza Vaccination Recommendations and Policies
    • 5.10.2. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitor Assessment
  • 6.3. Product Profiles - Major Brands
    • 6.3.1. Fluzone
    • 6.3.2. Vaxigrip/Mutagrip
    • 6.3.3. Fluarix/FluLaval
    • 6.3.4. FluMist
    • 6.3.5. Fluzone High-Dose
    • 6.3.6. Fluad
    • 6.3.7. Fluzone ID (Intradermal)/Intanza
    • 6.3.8. Optaflu/Flucelvax
    • 6.3.9. Flublok
    • 6.3.10. Fluvirin
    • 6.3.11. Afluria
    • 6.3.12. Influvac
    • 6.3.13. Agrippal

7. Opportunity and Unmet Need

  • 7.1. Overview
  • 7.2. Unmet Needs
    • 7.2.1. Higher level of patient awareness
    • 7.2.2. Increased efficacy in the elderly and young children (<2 years old)
    • 7.2.3. Improved vaccine side-effect profiles
    • 7.2.4. More efficient vaccine manufacturing process
    • 7.2.5. More cost-effective vaccines
  • 7.3. Gap Analysis
  • 7.4. Opportunities
    • 7.4.1. Expanded breadth of protection against viral strains
    • 7.4.2. Increased duration of protection
    • 7.4.3. T-cell involvement

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Country
  • 8.3. Clinical Trials by Phase and Trial Status
  • 8.4. Promising vaccines in clinical development
    • 8.4.1. ASP7374 (UMN-0502)
    • 8.4.2. Influenza VLP Vaccine

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Sanofi
    • 9.3.2. AstraZeneca (MedImmune)
    • 9.3.3. Novartis
    • 9.3.4. GlaxoSmithKline
    • 9.3.5. CSL Biotherapies
    • 9.3.6. Abbott
    • 9.3.7. Protein Sciences Corporation
    • 9.3.8. Novavax

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. United Kingdom
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. China
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers
  • 10.10. India
    • 10.10.1. Forecast
    • 10.10.2. Key Events
    • 10.10.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Vaccine Coverage
    • 11.4.2. Vaccines Included
    • 11.4.3. Key Launch Dates
    • 11.4.4. Influenza Vaccine Tender System Assumptions
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Vaccine Assumptions
    • 11.4.7. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in this Study
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Authors
    • 11.7.2. Epidemiologists
    • 11.7.3. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Notable Influenza Pandemics
  • Table 2: Symptoms of Influenza
  • Table 3: United States, Sources of Vaccination Coverage Data
  • Table 4: France, Sources of Vaccination Coverage Data
  • Table 5: Germany, Sources of Vaccination Coverage Data
  • Table 6: Italy, Sources of Vaccination Coverage Data
  • Table 7: Spain, Sources of Vaccination Coverage Data
  • Table 8: United Kingdom, Sources of Vaccination Coverage Data
  • Table 9: Japan, Sources of Vaccination Coverage Data
  • Table 10: India and China, Sources of Vaccination Coverage Data
  • Table 11: Nine Markets, Seasonal Vaccination Coverage, N (%), 2012-2022
  • Table 12: Influenza Vaccination Recommendation Committees by Country
  • Table 13: Most Administered Influenza Vaccines by Country in the Global Markets, 2013
  • Table 14: Leading Influenza Vaccines, 2013
  • Table 15: Product Profile - Fluzone
  • Table 16: Fluzone SWOT Analysis, 2013
  • Table 17: Global Sales Forecasts ($m) for Fluzone, 2012-2022
  • Table 18: Product Profile - Vaxigrip
  • Table 19: Laboratory-Confirmed Influenza Infection Rates in Vaccine or Placebo Recipients and their Household Contacts
  • Table 20: Vaxigrip SWOT Analysis, 2013
  • Table 21: Global Sales Forecasts ($m) for Vaxigrip, 2012-2022
  • Table 22: Product Profile - Fluarix
  • Table 23: Fluarix SWOT Analysis, 2013
  • Table 24: Global Sales Forecasts ($m) for Fluarix, 2012-2022
  • Table 25: Product Profile - FluMist
  • Table 26: FluMist SWOT Analysis, 2013
  • Table 27: Global Sales Forecasts ($m) for FluMist, 2012-2022
  • Table 28: Product Profile - Fluzone High-Dose
  • Table 29: Non-inferiority comparison of Fluzone High-Dose and Standard-Dose Vaccines
  • Table 30: Fluzone High-Dose SWOT Analysis, 2013
  • Table 31: Global Sales Forecasts ($m) for Fluzone High-Dose, 2012-2022
  • Table 32: Product Profile - Fluad
  • Table 33: Fluad SWOT Analysis, 2013
  • Table 34: Global Sales Forecasts ($m) for Fluad, 2012-2022
  • Table 35: Product Profile - Fluzone ID/Intanza
  • Table 36: Non-inferiority Comparison of Fluzone ID and IM Vaccines
  • Table 37: Fluzone ID/Intanza SWOT Analysis, 2013
  • Table 38: Global Sales Forecasts ($m) for Fluzone ID/Intanza, 2012-2022
  • Table 39: Product Profile - Optaflu/Flucelvax
  • Table 40: Optaflu/Flucelvax SWOT Analysis, 2013
  • Table 41: Global Sales Forecasts ($m) for Optaflu/Flucelvax, 2012-2022
  • Table 42: Product Profile - Flublok
  • Table 43: Flublok SWOT Analysis, 2013
  • Table 44: Global Sales Forecasts ($m) for Flublok, 2012-2022
  • Table 45: Product Profile - Fluvirin
  • Table 46: Immunogenicity of Agrippal and Fluvirin
  • Table 47: Fluvirin SWOT Analysis, 2013
  • Table 48: Global Sales Forecasts ($m) for Fluvirin, 2012-2022
  • Table 49: Product Profile - Afluria
  • Table 50: Afluria SWOT Analysis, 2013
  • Table 51: Global Sales Forecasts ($m) for Afluria, 2012-2022
  • Table 52: Product Profile - Influvac
  • Table 53: Influvac SWOT Analysis, 2013
  • Table 54: Global Sales Forecasts ($m) for Influvac, 2012-2022
  • Table 55: Product Profile - Agrippal
  • Table 56: Agrippal SWOT Analysis, 2013
  • Table 57: Global Sales Forecasts ($m) for Agrippal, 2012-2022
  • Table 58: Overall Unmet Needs - Current Level of Attainment, 2013
  • Table 59: Clinical Unmet Needs - Gap Analysis, 2013
  • Table 60: Seasonal Influenza - Clinical Trials by Phase and Status, 2013
  • Table 61: Seasonal Influenza Vaccines - Phase Pipeline, 2013
  • Table 62: Product Profile - ASP7374 (UMN-0502)
  • Table 63: ASP7374 (UMN-0502) SWOT Analysis, 2013
  • Table 64: Global Sales Forecasts ($m) for ASP7374 (UMN-0502), 2012-2022
  • Table 65: Product Profile - Influenza VLP Vaccine
  • Table 66: Influenza VLP Vaccine SWOT Analysis, 2013
  • Table 67: Global Sales Forecasts ($m) for Influenza VLP Vaccine, 2012-2022
  • Table 68: Key Companies in the Seasonal Influenza Vaccine Market, 2013
  • Table 69: Sanofi's Seasonal Influenza Vaccine Portfolio Assessment, 2013
  • Table 70: Sanofi SWOT Analysis, 2013
  • Table 71: AstraZeneca's Seasonal Influenza Vaccine Portfolio Assessment, 2013
  • Table 72: AstraZeneca SWOT Analysis, 2013
  • Table 73: Novartis' Seasonal Influenza Vaccine Portfolio Assessment, 2013
  • Table 74: Novartis SWOT Analysis, 2013
  • Table 75: GlaxoSmithKline's Seasonal Vaccine Portfolio Assessment, 2013
  • Table 76: GlaxoSmithKline's SWOT Analysis, 2013
  • Table 77: CSL Biotherapies' Seasonal Vaccine Portfolio Assessment, 2013
  • Table 78: CSL Biotherapies SWOT Analysis, 2013
  • Table 79: Abbott's Seasonal Vaccine Portfolio Assessment, 2013
  • Table 80: Abbott SWOT Analysis, 2013
  • Table 81: Protein Science's Seasonal Vaccine Portfolio Assessment, 2013
  • Table 82: Protein Sciences SWOT Analysis, 2013
  • Table 83: Novavax's Seasonal Vaccine Portfolio Assessment, 2013
  • Table 84: Novavax SWOT Analysis, 2013
  • Table 85: Global Sales Forecasts ($m) for Influenza Vaccines, 2012-2022
  • Table 86: Influenza Vaccine Market - Drivers and Barriers, 2013
  • Table 87: Sales Forecasts ($m) for Influenza Vaccines in the United States, 2012-2022
  • Table 88: Key Events Impacting Sales of Influenza Vaccines in US, 2013
  • Table 89: US Influenza Vaccine Market - Drivers and Barriers, 2013
  • Table 90: Sales Forecasts ($m) for Influenza Vaccines in France, 2012-2022
  • Table 91: Key Events Impacting Sales of Influenza Vaccines in France, 2013
  • Table 92: French Influenza Vaccine Market - Drivers and Barriers, 2013
  • Table 93: Sales Forecasts ($m) for Influenza Vaccines in Germany, 2012-2022
  • Table 94: Key Events Impacting Sales of Influenza Vaccines in Germany, 2013
  • Table 95: German Influenza Vaccine Market - Drivers and Barriers, 2013
  • Table 96: Sales Forecasts ($m) for Influenza Vaccines in Italy, 2012-2022
  • Table 97: Key Events Impacting Sales of Influenza Vaccines in Italy, 2013
  • Table 98: Italian Influenza Vaccine Market - Drivers and Barriers, 2013
  • Table 99: Sales Forecasts ($m) for Influenza Vaccines in Spain, 2012-2022
  • Table 100: Key Events Impacting Sales of Influenza Vaccines in Spain, 2013
  • Table 101: Spanish Influenza Vaccine Market - Drivers and Barriers, 2013
  • Table 102: Sales Forecasts ($m) for Influenza Vaccines in the United Kingdom, 2012-2022
  • Table 103: Key Events Impacting Sales for Influenza Vaccines in UK, 2013
  • Table 104: UK Influenza Vaccine Market - Drivers and Barriers, 2013
  • Table 105: British Influenza Vaccine Uptake Scenarios for Childhood Influenza Vaccination Program, 2012-2022 (in millions)
  • Table 106: Sales Forecasts ($m) for Influenza Vaccines in Japan, 2012-2022
  • Table 107: Key Events Impacting Sales of Influenza Vaccines in Japan, 2013
  • Table 108: Japanese Influenza Vaccine Market - Drivers and Barriers, 2013
  • Table 109: Sales Forecasts ($m) for Influenza Vaccines in China, 2012-2022
  • Table 110: Key Events Impacting Sales of Influenza Vaccines in China, 2013
  • Table 111: Chinese Influenza Vaccine Market - Drivers and Barriers, 2013
  • Table 112: Sales Forecasts ($m) for Influenza Vaccines in India, 2012-2022
  • Table 113: Key Events Impacting Sales of Influenza Vaccines in India, 2013
  • Table 114: Indian Influenza Vaccine Market - Drivers and Barriers, 2013
  • Table 115: Epidemiology and Market Forecast Chinese Influenza Vaccination Rates (%), 2012-2022
  • Table 116: Key Launch Dates
  • Table 117: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Influenza Virus Structure
  • Figure 2: United States, Seasonal Influenza Vaccination Coverage, 2001-2022
  • Figure 3: France, Seasonal Influenza Vaccination Coverage, 2001-2022
  • Figure 4: Germany, Seasonal Influenza Vaccination Coverage, 2001-2022
  • Figure 5: Italy, Seasonal Influenza Vaccination Coverage, 2001-2022
  • Figure 6: Spain, Seasonal Influenza Vaccination Coverage, 2001-2022
  • Figure 7: United Kingdom, Seasonal Influenza Vaccination Coverage, 2001-2022
  • Figure 8: Japan, Seasonal Influenza Vaccination Coverage, 2001-2022
  • Figure 9: China, Seasonal Influenza Vaccination Coverage, 2001-2022
  • Figure 10: India, Seasonal Influenza Vaccination Coverage, 2001-2022
  • Figure 11: All Markets, Seasonal Influenza Vaccination Coverage (N), 2012-2022
  • Figure 12: Seasonal Influenza Vaccines - Clinical Trials by Country, 2013
  • Figure 13: Competitive Assessment of Influential Seasonal Influenza Vaccines, 2012-2022
  • Figure 14: Company Portfolio Gap Analysis in Seasonal Influenza Vaccines, 2012-2022
  • Figure 15: Global Sales of Influenza Vaccines by Region, 2012-2022
  • Figure 16: Sales for Influenza Vaccines in the United States by Route of Administration, 2012-2022
  • Figure 17: Sales for Influenza Vaccines in France by Route of Administration, 2012-2022
  • Figure 18: Sales for Influenza Vaccines in Germany by Route of Administration, 2012-2022
  • Figure 19: Sales for Influenza Vaccines in Italy by Route of Administration, 2012-2022
  • Figure 20: Sales for Influenza Vaccines in Spain by Route of Administration, 2012-2022
  • Figure 21: Sales for Influenza Vaccines the United Kingdom by Route of Administration, 2012-2022
  • Figure 22: Sales for Influenza Vaccine in China by Route of administration, 2012-2022
  • Figure 23: Sales for Influenza Vaccines in India by Route of Administration, 2012-2022
Back to Top